A company right here in our area is working to fight the super-bug threat.
Josh Bryson is the Chief Scientific Officer for the technology company, Techulon, in Blacksburg.
He's part of a group of Virginia Tech graduates who are developing a drug to treat super bugs like staff infections.
"I think most people know someone who's gone to the hospital and it's resulted in a nasty somewhat drug-resistant staff infection, and there's even more resistant strains that have evolved recently," Josh Bryson, Techulon CSO says.
The product will also treat other drug-resistant infections, which Bryson says is a growing problem in general. Right now. superbugs are creating $30 billion health care costs and leaving people in hospitals for up to 3 weeks to be treated and causing 100,000 deaths a year.
The Defense Advance Research Projects Agency is validating Techulon's work, by giving them an additional $1.75 million to help continue their research.
"There couldn't be a better endorsement from an agency," Byrson says.